Search All UT System Experts

A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer

C. Casey Cunningham, Jon T. Holmlund, Joan H. Schiller, Richard S. Geary, T. Jesse Kwoh, Andrew Dorr, John Nemunaitis

Research output: Contribution to journal › Article › peer-review

135 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences